Clinical trial NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Official title: A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Advanced Solid Tumor
BRAF V600 Mutation
Keywords: Melanoma
Colorectal Cancer
Glioblastoma
Cholangiocarcinoma
Non-small Cell Lung Cancer
Thyroid Cancer
Ovarian Cancer
Lead sponsor: ABM Therapeutics Corporation
Sponsor class: INDUSTRY
First posted: 2019-12-09
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Study consists of Three Parts:

Part A: ABM-1310 Dose Escalation and MTD/RP2D Dose Confirmation

Part B: Combination agent (ABM-1310 and cobimetinib (Cotellic®)) Dose Escalation and MTD/RP2D Dose Confirmation

Part C: Dose Expansion (ABM-1310 Monotherapy/Combination Therapy)
Primary purpose: TREATMENT

Brief summary: This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy.

Detailed description: This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in patients with documented BRAF V600 mutation, or in combination with cobimetinib (Cotellic®) in adult patients who have documented BRAF mutation and progressive disease or intolerance to at least one prior line of systemic therapy. The primary objectives of this study are to determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase II Dose (RP2D) of both single agent and combination treatment and to assess the safety and tolerability of ABM-1310 as a monotherapy and in combination.

Study consists of three Parts:

Part A: The starting dose of ABM-1310 is 25 mg po bid, and dose escalation will be guided by a "3+3" design. ABM-1310 will be administered twice daily on a continuous schedule. Each treatment cycle consists of 28 days.

Part B: The starting dose of ABM-1310 will be a dose below the MTD that has been demonstrated to be safe in Part A Monotherapy. A classic "3+3" design will guide the dose escalation. At each dose level, ABM-1310 will be administered in combination with 60 mg cobimetinib (Cotellic ®) once daily (qd) for the first 21 days of each 28-day treatment cycle.

Part C:

* In C-1 (Monotherapy - Primary CNS Tumors) and C-2 (Monotherapy - Advanced or Metastatic solid tumors excluding Primary CNS tumors with or without Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
* In C-3 (Combination therapy - Advanced/Metastatic Solid Tumors including Primary CNS Tumors but excluding Melanoma with Brain Metastsis) and C-4 (Combination therapy - Melanoma with Brain Metastasis), continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B, in combination with cobimetinib (Cotellic®) 60 mg administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.

Dose limiting toxicity (DLT) will be evaluated and managed per the pre-defined DLT criteria and rules specified in the protocol. MTD and/or RP2D will be confirmed in a dose confirmation cohort.

Eligibility criteria: Inclusion Criteria:

1. Male and female subjects age 18 years and older who are able to sign informed consent and to comply with the protocol
2. Patients with histologically or cytologically-documented, locally advanced, or metastatic solid tumor malignancy that has either (a) progressed on at least one line of prior standard systemic therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the patient or treating physician. There is no limit to the number of prior treatment regimens

   * Part A: Patients with advanced or metastatic solid tumors with documentation of positive BRAF V600E mutation, or any other BRAF V600 mutation is required for enrollment
   * Part B: Patients with advanced or metastatic solid tumors with documentation of any BRAF mutation.
   * Part C:

     1. C-1: Patients with primary central nervous system (CNS) tumors and documentation of positive BRAF V600 mutation
     2. C-2: Patients with advanced or metastatic solid tumors and documentation of positive BRAF V600 mutation excluding primary CNS tumor
     3. C-3: Patients with advanced or metastatic solid tumors and documentation of positive BRAF mutation including primary CNS tumors but excluding melanoma with brain metastasis
     4. C-4: Patients with melanoma with brain metastasis and documentation of positive BRAF mutation

   Patients with active or stable brain metastasis that are asymptomatic, or that are symptomatic treated with a total daily dose of no more than 4 mg of dexamethasone (or equivalent) that is stable or tapering for at least 2 weeks prior to first treatment are eligible for enrollment. Patients with neurologic signs and symptoms who are not being treated with steroids are eligible and should have no experience of seizure within 2 weeks prior to first treatment.
3. Must have at least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors or the RANO criteria for primary CNS tumors, such as gliomas.

   * For solid tumor with Brain Metastases:
   * Measurable brain lesions that are 0.5 - 3 cm in longest diameter as defined by the modified RECIST V1.1 criteria are allowed.
   * Brain lesion size \> 3 cm is not eligible.
4. ECOG performance status of 0 or 1 or Karnofsky performance status of ≥ 70
5. Adequate organ function confirmed at screening and within 28 days of initiating treatment, as evidenced by:

   * Absolute Neutrophil Count (ANC) ≥ 1.0 x 10\^9/L
   * Hemoglobin (Hgb) ≥ 9 g/dl
   * Platelets (Plt) ≥ 100 x 10\^9/L
   * AST/ALT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present
   * Total bilirubin ≤ 1.5 x ULN, or direct bilirubin \<ULN for patients with total bilirubin levels \>1.5 ULN
   * Serum creatinine \<1.5 x ULN or measured or calculated (per institutional standard) creatinine clearance of \> 60 mL/min.
6. Negative pregnancy test within 72 hours before starting study treatment in all pre-menopausal women and women \<12 months after the onset of menopause
7. Male and female subjects must agree to take sufficient contraceptive methods to avoid pregnancy before first dose of study treatment, during the study, and for at least 3 months after ceasing study treatment

Exclusion Criteria:

1. Women who are pregnant or breast-feeding
2. Women of child-bearing potential (WOCBP) who does not use adequate birth control
3. Patients with any hematologic malignancy. This includes leukemia, lymphoma, and multiple myeloma
4. Have a second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results
5. Patients with carcinomatous meningitis (leptomeningeal disease (LMD))
6. Patients with history of stroke ≤ 6 months prior to starting study drug
7. Patients who have had an experience of seizure within 14 days prior to first treatment
8. Impaired cardiac function or clinically significant cardiac diseases, including but not limited to any of the following:

   * Left Ventricular Ejection Fraction (LVEF) \< 45% as determined by MUGA scan or ECHO
   * Congenital long QT syndrome
   * QTcF ≥ 450 msec (mean) on screening (Triplicate 12-Lead ECG)
   * Unstable angina pectoris ≤ 6 months prior to starting study drug
   * Acute myocardial infarction ≤ 6 months prior to starting study drug
   * Use of pacemaker
9. Patients with

   * Unresolved diarrhea ≥ CTCAE Grade 2, or
   * Impairment of gastrointestinal (GI) function, or
   * GI disease or conditions that may significantly alter the absorption of ABM-1310 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
10. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertriglyceridemia \[triglycerides \>500 mg/dL\], active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
11. Extensive prior radiotherapy to more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years
12. Patients who have received chemotherapy, targeted therapy or immunotherapy ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy, except:

    * ≤ 6 weeks for nitrosourea or mitomycin-C
    * ≤ 5 half-lives or 2 weeks for small molecule inhibitor treatment, whichever is longer
13. Patients who have received wide field radiotherapy ≤ 4 weeks, limited field radiation for palliation ≤ 2 weeks, prior whole-brain radiotherapy (WBRT) ≤ 4 weeks or stereotactic radiosurgery (SRS) ≤ 2 weeks (one week for patients with primary CNS tumor such as GBM or with brain metastasis) prior to starting study drug or patients who have not recovered from side effects of such therapy
14. Patients who have undergone major surgery ≤ 4 weeks in general prior to starting study drug or who have not recovered from side effects of such therapy. However, a minimum of 2 weeks recovery time from major surgery prior to starting study drug is acceptable if in investigator's opinion the patient has recovered from surgery.
15. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium or any other coumarin-derivative anticoagulants
16. Patients who have received systemic corticosteroids ≤ 2 weeks prior to starting study drug or who have not recovered from the side effects of such treatment. Therapeutic doses of corticosteroids up to 4 mg/day of dexamethasone, or equivalent are allowed. Note: Patients that are taking replacement doses of steroids are eligible
17. Patients who are currently receiving treatment with medication that has known risk to prolong the QT interval, and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug
18. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory; patients with well controlled HIV might be enrolled per investigator's discretion)
19. Known history of active infection with Hepatitis B (e.g., HBsAg reactive), or Hepatitis C (e.g., S RNA (qualitative) is detected)
20. History of alcohol or drug abuse ≤ 3 months prior to first dose
21. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's participation and compliance in the trial

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)
timeFrame: End of Cycle 1 (each cycle is 28 days) or up to treatment discontinuation (an average of 6 months)
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
timeFrame: Up to study discontinuation (an average of 1 year)
measure: Number of participants with abnormal laboratory values
timeFrame: Up to study discontinuation (an average of 1 year)
Secondary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
timeFrame: Up to 30 days from treatment discontinuation
measure: Number of participants with abnormal laboratory values
timeFrame: Up to 30 days from treatment discontinuation
measure: Area under the concentration time curve (AUC)
timeFrame: Up to Day 1 of Cycle 2 (each cycle is 28 days)
measure: Maximum plasma concentration (Cmax)
timeFrame: Up to Day 1 of Cycle 2 (each cycle is 28 days)
measure: Steady-state concentration (Css)
timeFrame: Up to Day 1 of Cycle 2 (each cycle is 28 days)
measure: Time to maximum plasma concentration (Tmax)
timeFrame: Up to Day 1 of Cycle 2 (each cycle is 28 days)
measure: Half-life (T1/2)
timeFrame: Up to Day 1 of Cycle 2 (each cycle is 28 days)
measure: Objective Response Rate (ORR)
timeFrame: Up to study discontinuation (an average of 1 year)
measure: Disease Control Rate (DCR)
timeFrame: Up to study discontinuation (an average of 1 year)
measure: Duration of Response (DOR)
timeFrame: Up to study discontinuation (an average of 1 year)
measure: Progression free survival (PFS)
timeFrame: Up to study discontinuation (an average of 1 year)
measure: Overall Survival (OS)
timeFrame: Up to study discontinuation (an average of 1 year)
measure: Time to Response (TTR)
timeFrame: Up to study discontinuation (an average of 1 year)
Other outcomes:
measure: Exploratory preliminary efficacy in patients by types of BRAF V600 mutation
timeFrame: Up to study discontinuation (an average of 1 year)
measure: Identification of major metabolite of ABM-1310 in patients who receive ABM-1310 monotherapy in Part C
timeFrame: Up to study discontinuation (an average of 1 year)
Locations:
city: San Francisco
country: United States
facility: University of California- San Francisco
state: California
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
city: Miami
country: United States
facility: University of Miami Hospital Sylvester Comprehensive Cancer Center
state: Florida
city: Chicago
country: United States
facility: Robert H. Lurie Comprehensive Cancer Center (Northwestern University)
state: Illinois
city: Detroit
country: United States
facility: Henry Ford Cancer Institute
state: Michigan
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: Houston
country: United States
facility: UTHealth Science Center Houston Department of Neurosurgery
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Sarina A Piha-Paul, M.D.
role: PRINCIPAL_INVESTIGATOR
References: